EACS 2023

EACS 2023
October 18-21, 2023
Warsaw, Poland

European AIDS Conference.

Explore more information for Gilead HIV / AIDS therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (8)

    Association of Susceptibility to Broadly Neutralizing Antibodies and Presence of Capsid CTL Epitopes During Acute HIV-1 Infection

    • Author(s): Selzer, L
    • bnab-combination-(gs-5423,-gs-2872)
    • HIV / AIDS

    Resistance Analysis of Long-Acting Lenacapavir in Heavily Treatment‑Experienced People with HIV after 104 Weeks of Treatment

    • Author(s): Margot, N
    • lenacapavir
    • HIV / AIDS

    Assessing Phenotypic Effect of Integrase Strand Transfer Inhibitor (INSTI)-Based Resistance Substitutions Linked to Failures on Cabotegravir

    • Author(s): D'Antoni, M
    • biktarvy
    • elvitegravir
    • HIV / AIDS

    Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-experienced (TE) people with HIV (PWH) with baseline symptoms of depression, anxiety or insomnia (DAI) in the observational BICSTaR study

    • Author(s): Esser, S
    • biktarvy
    • HIV / AIDS

    Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in antiretroviral treatmentnaïve (TN) and -experienced (TE) people with HIV (PWH): 3-year effectiveness and safety outcomes in the BICSTaR observational cohort

    • Author(s): Sabranski, M
    • biktarvy
    • HIV / AIDS

    Insights and experiences from the CAPELLA trial: perspectives of healthcare professionals and study coordinators on Lenacapavir use amongst heavily treatment-experienced people with HIV

    • Author(s): Fang, J
    • lenacapavir
    • HIV / AIDS

    Follow-up of injection site reactions in clinical studies of people using lenacapavir every 6 months for HIV treatment

    • Author(s): Castagna, A
    • lenacapavir
    • HIV / AIDS

    Restarting bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) after virologic rebound: a pooled analysis of studies in people with HIV-1

    • Author(s): Pozniak, A
    • biktarvy
    • HIV / AIDS